Cannabis Industry Q1 2026 Review: Sales Trends, Market Movements, and What Lies Ahead
The first quarter of 2026 is in the books, and the cannabis industry’s performance tells a story of maturation, divergence, and cautious optimism. National legal cannabis sales reached an estimated $8.2 billion in Q1, a 9.4% increase over Q1 2025 — solid growth but a clear step down from the double-digit surges of 2021–2023. The industry is no longer a rocket ship. It is becoming a real business, with all the complexity that entails.
Here is what happened, what it means, and what to expect for the rest of the year.
National Sales: Steady Growth, Shifting Composition
The $8.2 billion Q1 figure represents a continuation of the growth trajectory that saw full-year 2025 sales land at approximately $31.5 billion nationally. But the composition of that growth has changed meaningfully.
Recreational sales grew 7.1% year-over-year, driven primarily by new market maturation in New York, Ohio, and Maryland. These states, which opened adult-use dispensaries in 2024 and early 2025, are now hitting their stride as retail footprints expand and consumer habits normalize.
Medical sales, which had been declining nationally as recreational markets cannibalized patient counts, stabilized in Q1 at roughly $6.8 billion annualized. The stabilization is attributed to rescheduling tailwinds — the federal reclassification of cannabis from Schedule I to Schedule III, finalized in late 2025, has made medical cannabis programs more attractive to both patients and physicians who previously avoided the space.
Beverage and edible categories outpaced flower and vape growth for the third consecutive quarter. Infused beverages grew an estimated 28% year-over-year in Q1, the fastest-growing product category in the industry. If you are curious about what goes into these products on the manufacturing side, our look at cannabis gummy manufacturing processes provides a detailed breakdown.
State-by-State Highlights
The national numbers mask enormous state-level variation. Q1 2026 was defined by a handful of standout performers and a few concerning declines.
Winners
New York posted its strongest quarter yet, with recreational sales exceeding $620 million. The state’s notoriously slow licensing process finally began yielding results in late 2025, and Q1 saw a wave of new dispensary openings — particularly in the boroughs of New York City and the Hudson Valley corridor. Licensed retail locations now number over 320 statewide, up from fewer than 100 a year ago. The illicit market remains a major competitor, but legal market momentum is unmistakable.
Ohio surprised analysts by reaching $185 million in its first full quarter of recreational sales, outpacing projections by roughly 15%. The Buckeye State benefits from a large population with no nearby recreational markets (Michigan excepted), driving strong in-state demand and cannabis tourism from neighboring Kentucky, West Virginia, and Pennsylvania.
Florida, still medical-only but with the largest patient registry in the country at over 900,000 active cardholders, posted $1.1 billion in annualized Q1 sales. The state’s vertical integration model has been criticized for limiting competition, but it has produced a well-capitalized, operationally efficient market that continues to grow.
Underperformers
Oregon saw its eighth consecutive quarter of flat or declining sales, with Q1 revenue down 3.2% year-over-year. Oversupply and aggressive price compression have made Oregon one of the cheapest cannabis markets in the country — excellent for consumers, devastating for operators. Average retail prices per gram of flower fell below $4.00 in Q1, a level at which many small cultivators cannot operate profitably.
California, the world’s largest cannabis market, grew just 2.1% in Q1 — essentially flat after inflation adjustment. The state’s burdensome tax structure, byzantine local permitting requirements, and thriving illicit market continue to throttle the regulated industry. Multiple operator bankruptcies in Q1 underscored the challenges.
Consolidation Accelerates
The merger and acquisition landscape in Q1 was the most active since the 2021 SPAC boom, but with a fundamentally different character. The deals of 2021 were speculative — companies buying growth at any price. The deals of Q1 2026 are strategic and often distressed.
Three major transactions defined the quarter:
- Curaleaf’s acquisition of a regional Ohio–Pennsylvania operator for $340 million, giving the multi-state operator a dominant footprint in two of the most promising eastern markets.
- A major private equity consortium’s $500 million investment in a portfolio of California cultivation assets purchased at steep discounts from distressed sellers.
- The merger of two mid-tier Canadian licensed producers, continuing the consolidation of Canada’s oversaturated market that has been underway since 2023.
The pattern is clear: well-capitalized companies are using the current environment to acquire assets cheaply, positioning for what they expect to be a more favorable regulatory landscape — including potential interstate commerce — in the next 2–3 years.
For entrepreneurs entering the space, the consolidation wave creates both challenges and opportunities. Our coverage of cannabis co-working spaces and incubators explores the support infrastructure that is helping new operators find their footing in this competitive environment.
Rescheduling Impacts: Early Returns
The reclassification of cannabis from Schedule I to Schedule III, which took effect in October 2025, was the most significant federal cannabis policy change in decades. Its Q1 impacts are beginning to come into focus.
Tax relief is real and significant. The elimination of Section 280E tax restrictions — which had prevented cannabis businesses from deducting standard business expenses — delivered an immediate boost to operator margins. Multi-state operators reported effective tax rate reductions of 15–25 percentage points. For an industry that has operated under punitive taxation for years, this is transformative.
Banking access is improving but incomplete. More banks and credit unions are willing to serve cannabis businesses post-rescheduling, and the cost of banking services has declined. However, major national banks remain cautious, and the SAFE Banking Act — which would provide explicit federal protection for cannabis financial services — has not yet passed. For a deeper look at how federal cannabis policy is evolving and its implications for employment, see our analysis of cannabis and federal employment security clearances.
Research is expanding rapidly. Schedule III classification makes it dramatically easier for universities and research institutions to study cannabis. NIH funding for cannabinoid research doubled in Q1 compared to the same period in 2025, and multiple clinical trials that were previously impossible under Schedule I are now underway.
Pricing Trends
Wholesale cannabis prices continued their long-term decline in most mature markets during Q1, but the pace of decline is slowing.
- Wholesale indoor flower: $1,200–$1,800/lb nationally (down 8% YoY)
- Wholesale outdoor/greenhouse flower: $400–$800/lb (down 12% YoY)
- Distillate: $3,500–$5,500/kg (relatively stable)
- Live resin/rosin: $8,000–$14,000/kg (up 5% YoY — premium concentrates bucking the trend)
Retail prices are holding up better than wholesale, as dispensaries maintain margins through branding, product differentiation, and loyalty programs. The premium concentrate category is a bright spot, with consumer willingness to pay for quality keeping margins healthy.
Employment and Workforce
The legal cannabis industry employed an estimated 440,000 full-time-equivalent workers at the end of Q1, up from approximately 410,000 a year earlier. New York, Ohio, and Maryland accounted for the majority of new positions.
However, the workforce picture is not uniformly positive. Layoffs at several multi-state operators offset new market hiring, and wage growth has been modest. The industry’s transition from startup-culture compensation (equity-heavy, salary-light) to mature-industry norms is ongoing and occasionally painful.
What to Watch in Q2–Q4 2026
Several factors will shape the rest of the year:
Interstate commerce pilots. Several states are exploring limited interstate cannabis trade agreements. If any launch in 2026, even as pilots, the implications for pricing, supply chains, and competitive dynamics will be enormous.
Federal banking legislation. The SAFE Banking Act has bipartisan support and is widely expected to pass in some form by year-end. Its passage would be the most impactful remaining regulatory unlock for the industry.
New market launches. Kentucky and Pennsylvania are both on track to open recreational sales before year-end, potentially adding $1–2 billion in annualized market capacity.
Continued consolidation. Expect more M&A activity, particularly as 280E relief gives profitable operators more capital to deploy and distressed assets remain available at attractive prices.
The cannabis industry in Q1 2026 looks less like the Wild West and more like an established consumer goods sector — complete with margin pressure, competitive dynamics, regulatory complexity, and, for well-positioned operators, real profitability. The companies that thrive over the rest of 2026 will be the ones that have already internalized this reality: cannabis is no longer a movement. It is an industry. And the rules of business apply.